Search Results - "Nogová, L."

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG) by Nogová, L., Reineke, T., Eich, H. T., Josting, A., Müller-Hermelink, H. K., Wingbermühle, K., Brillant, C., Gossmann, A., Oertel, J., Bollen, M. V., Müller, R.-P., Diehl, V., Engert, A.

“…Background: Since there are no randomized studies, the treatment of choice for patients with early stage lymphocyte-predominant Hodgkin's lymphoma (LPHL)…”
Get full text

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer by de Boer, R., Humblet, Y., Wolf, J., Nogová, L., Ruffert, K., Milenkova, T., Smith, R., Godwood, A., Vansteenkiste, J.

“…Background: Vandetanib (ZACTIMA™; ZD6474) is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor…”
Get full text

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer by Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M.A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krüger, S., Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K -O, Thomas, R., Zander, T., Schultheis, A.M., Büttner, R., Wolf, J.

“…We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). ALK-rearranged stage…”
Get full text

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors by Soria, J.-C., Shepherd, F.A., Douillard, J.-Y., Wolf, J., Giaccone, G., Crino, L., Cappuzzo, F., Sharma, S., Gross, S.H., Dimitrijevic, S., Di Scala, L., Gardner, H., Nogova, L., Papadimitrakopoulou, V.

“…Treatment options are scarce in pretreated advanced non-small-cell lung cancer (NSCLC) patients. RAD001, an oral inhibitor of the mammalian target of rapamycin…”
Get full text

Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials by Sieniawski, M., Reineke, T., Josting, A., Nogova, L., Behringer, K., Halbsguth, T., Fuchs, M., Diehl, V., Engert, A.

“…Infertility is one of the most significant side-effects in long-term survivors of successfully treated Hodgkin's lymphoma (HL). The fertility status was…”
Get full text

Secondary Amenorrhea After Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin’s Lymphoma Study Group by BEHRINGER, Karolin, BREUER, Kai, REINEKE, Thorsten, MAY, Michael, NOGOVA, Lucia, KHMM, Beate, SCHMITZ, Tatiana, WILDT, Ludwig, DIEHL, Volker, ENGERT, Andreas

“…Long-term survivors of successfully treated Hodgkin's lymphoma (HL) are at risk for late complications. Among these, infertility for female patients is of…”
Get full text

Current antiangiogenic agents in oncology and ophthalmology by Cernak, M, Nogova, L

“…Antiangiogenic drugs are approved for many cancer types for longer than a decade. Furthermore, several antiangiogenic agents are approved for local application…”
Get more information

Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients by Abdulla, D.S., Ruge, M., Scheffler, M., Nogova, L., Koleczko, S., Persigehl, T., Grau, S., Drzezga, A., Kobe, C., Buettner, R., Galldiks, N., Wolf, J.

Get full text

Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC) by Scheffler, M., Frank, R., Ihle, M.A., Abdulla, D.S., Koleczko, S., Nogova, L., Holzem, A., Chanra, T., Riedel, R., Michels, S., Fischer, R.N., Kron, A., Merkelbach-Bruse, S., Buettner, R., Wolf, J.

Get full text

FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC by Nogova, L., Malchers, F., Hillmer, A., Merkelbach-Bruse, S., Pinto, A., Woempner, C., Riedel, R., Scheffler, M., Michels, S., De Porre, P., Santiago-Walker, A., Fischer, R.N., Abdulla, D.S., Thomas, R., Buettner, R., Wolf, J.

Get full text

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib by Bos, M, Gardizi, M, Schildhaus, H.U, Heukamp, L.C, Geist, T, Kaminsky, B, Zander, T, Nogova, L, Scheffler, M, Dietlein, M, Kobe, C, Holstein, A, Maintz, D, Büttner, R, Wolf, J

“…Abstract A 55-year-old Caucasian woman with lung adenocarcinoma stage IV presented with repeated relapse after treatment with cytotoxic chemotherapy…”
Get full text

Economic Burden of Clinical Trials in Lung Cancer in a German Comprehensive Cancer Center by Kron, F, Kostenko, A, Scheffler, M, Müller, D, Glossmann, J.-P, Fischer, R, Michels, S, Nogova, L, Hallek, M, Zander, T, Wolf, J

“…Highlights • Lung cancer research has a strong focus on early proof of concept trials. • Trials with low patient numbers/investigator-initiated trials are…”
Get full text

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial by Michels, S., Massutí, B., Vasyliv, I., Stratmann, J., Frank, J., Adams, A., Felip, E., Grohé, C., Rodriguez-Abreu, D., Bischoff, H., Carcereny i Costa, E., Corral, J., Pereira, E., Fassunke, J., Fischer, R.N., Insa, A., Koleczko, S., Nogova, L., Reck, M., Reutter, T., Riedel, R., Schaufler, D., Scheffler, M., Weisthoff, M., Provencio, M., Merkelbach-Bruse, S., Hellmich, M., Sebastian, M., Büttner, R., Persigehl, T., Rosell, R., Wolf, J.

“…In 2019, we reported the first efficacy and safety analysis of EUCROSS, a phase II trial investigating crizotinib in ROS1 fusion-positive lung cancer. At that…”
Get full text

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study by Josting, A., Sieniawski, M., Glossmann, J.-P., Staak, O., Nogova, L., Peters, N., Mapara, M., Dörken, B., Ko, Y., Metzner, B., Kisro, J., Diehl, V., Engert, A.

“…Background: Combination chemotherapy can cure patients with non-Hodgkin's lymphoma (NHL), but those who suffer treatment failure or relapse still have a poor…”
Get full text

BEACOPP and COPP ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - Results of the German Hodgkin Study Group by Rüffer, J. U., Ballova, V., Glossmann, J., Sieber, M., Franklin, J., Nogova, L., Diehl, V., Josting, A.

“…Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results. We retrospectively analysed…”
Get full text

SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification by Satoh, T., Barthélémy, P., Nogova, L., Honda, K., Iwasa, S., Lee, K., Rha, S., Ajani, J., Hangai, N., Liu, S., Kremer, J., Mina, M., Shitara, K.

Get full text

1374P Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients by Glaser, M., Braegelmann, S., Rasokat, A., Nogova, L., Wömpner, C., Schmitz, J., Bitter, E., Terjung, I., Eisert, A., Fischer, R.N., John, F., Michels, S., Riedel, R., Ruge, L.V., Scharpenseel, H., Siebolts, U., Merkelbach-Bruse, S., Büttner, R., Wolf, J., Scheffler, M.

Get full text

P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases by Meißner, A, Gutsche, R, Galldiks, N, Kocher, M, Jünger, S, Eich, M, Nogova, L, Schmidt, N, Ruge, M, Goldbrunner, R, Proescholdt, M, Grau, S, Lohmann, P

“…Abstract BACKGROUND The expression level of programmed cell death ligand 1 (PDL-1) might be an indicator for response to immunotherapy using checkpoint…”
Get full text

9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential by Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wömpner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R.N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Büttner, R., Wolf, J., Scheffler, M.

Get full text

991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB) by Kron, A., Scheffler, M., Ihle, M., Michels, S., Süptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R.N., Eisert, A.K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Büttner, R., Wolf, J.

Get full text